What does it take to create the perfect bispecific?
That's what we asked Volker Schellenberger, President and Chief Technology Officer at Amunix Pharmaceuticals in a very first episode of the Life Sciences podcast.
As co-founder of Amunix, Schellenberger is the lead inventor of the company’s XTEN as well as XPAT platforms of protease-activated T-cell engagers. In conversation with Conference Producer Eden Turner, he discussed the key steps to producing the ultimate bispecific, including the most important considerations for designing a platform and notable trends in antibody engineering techniques.
Listen to the full podcast episode below or click here to listen on Soundcloud.
